Načítá se...
Rho kinase inhibitors for treatment of glaucoma
Affecting 60 million patients, glaucoma is the second leading cause of blindness worldwide. Despite the availability of multiple medical and surgical treatments with effective intraocular pressure lowering, many patients still progress to become visually handicapped from glaucoma due to therapeutic...
Uloženo v:
| Vydáno v: | Expert Rev Ophthalmol |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6319899/ https://ncbi.nlm.nih.gov/pubmed/30613208 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1586/eop.11.65 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|